Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Kurtz, JE; Kaminsky, MC; Floquet, A; Veillard, AS; Kimmig, R; Dorum, A; Elit, L; Buck, M; Petru, E; Reed, N; Scambia, G; Varsellona, N; Brown, C; Pujade-Lauraine, E; on behalf of Gynecologic Cancer Intergroup.
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
ANN ONCOL. 2011; 22(11): 2417-2423.
Doi: 10.1093/annonc/mdr001
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Petru Edgar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin-pegylated liposomal doxorubicin (C-PLD) with carboplatin-paclitaxel (C-P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients >= 70 years. Patients and methods: Nine hundred and seventy-six patients with taxane-pretreated ROC relapsing >6 months after first-or second-line platinum-based therapy were randomly assigned to 4-weekly C area under the curve (AUC) 5 plus PLD 30 mg/m(2) or 3-weekly C AUC 5 plus P 175 mg/m(2) for six or more cycles. Results: One hundred and fifty-seven (16%) patients >= 70 years (median: 74 years, C-PLD; 73 years, C-P; range 70-82 years) were included (n = 71, C-PLD; n = 86, C-P). In comparing elderly and younger, elderly patients experienced fewer grade >= 2 allergic reactions (P = 0.005) but more grade >= 2 sensory neuropathy (P = 0.007). Myelosuppression did not differ with age. Elderly patients completed planned treatment as frequently as younger (79%, C-PLD; 82%, C-P). In comparing arms within elderly patients, C-P was associated with more grade >= 2 alopecia, sensory neuropathy, arthralgia/myalgia (P < 0.001 for all), severe leukopenia plus febrile neutropenia; C-PLD was associated with more grade >= 2 hand-foot syndrome (P = 0.005). Median progression-free survival was 11.6 months (C-PLD) and 10.3 months (C-P; P = 0.44). Conclusions: Patients >= 70 years experienced more neuropathy, with a higher incidence in the C-P arm. Similar to all study patients, C-PLD provided a better therapeutic index with less toxicity than C-P in elderly women with platinum-sensitive ROC.
- Find related publications in this database (using NLM MeSH Indexing)
- Age Factors -
- Aged -
- Aged, 80 and over -
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Carboplatin - administration and dosage
- Doxorubicin - administration and dosage
- Female -
- Humans -
- Neoplasm Recurrence, Local - drug therapy
- Ovarian Neoplasms - drug therapy
- Paclitaxel - administration and dosage
- Polyethylene Glycols - administration and dosage
- Quality of Life -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- carboplatin
- elderly
- ovarian cancer
- paclitaxel
- pegylated liposomal doxorubicin
- relapse